SUMOdulon, Inc. was incorporated in January 2023 with a single focus: making chemotherapy work better. We develop small molecule inhibitors that target the SUMOylation system — a cellular pathway cancer cells use to resist treatment. By blocking this pathway, our compounds restore cancer cell sensitivity to existing chemotherapeutic agents, improving outcomes without increasing toxicity. 

Every year, millions of patients are diagnosed with cancers that initially respond to chemotherapy — only to develop resistance. For these patients, resistance doesn't just mean treatment failure. It means running out of options.

SUMOdulon, Inc. is developing a solution that works with the treatments already trusted by oncologists worldwide. No new toxicity. No replacing what works. Just making it work better, for longer, for more patients.